NCT05931484View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

November 1, 2027

Primary Completion Date

November 1, 2028

Study Completion Date

November 1, 2028

Conditions

Parkinson Disease

Interventions

DRUG

Gemfibrozil

Oral Solution

DRUG

Placebo

Daily dose of Placebo

All Listed Sponsors

lead

Forest Hills Lab

INDUSTRY